IIT Madras Develops Precision Nanoinjection Platform to Improve Breast Cancer Drug Delivery
NEW DELHI, India — Researchers at the Indian Institute of Technology Madras have unveiled a groundbreaking nanoinjection drug delivery platform aimed at enhancing the treatment of breast cancer. This innovative technology promises to make breast cancer therapy safer, more effective, and less expensive.
The Challenge of Breast Cancer Treatment
Breast cancer is one of the leading causes of death among women globally. Traditional treatment methods, such as chemotherapy and radiation, often have detrimental effects on healthy tissues due to the systemic exposure to potent drugs. This has led to a pressing need for more targeted and efficient treatment options.
Introducing the Nanoinjection Platform
The newly developed platform utilizes thermally stable nanoarchaeosomes that are loaded with the anticancer drug doxorubicin. These nanoarchaeosomes are delivered directly into cancer cells through vertically aligned silicon nanotubes etched onto a silicon wafer. This method allows for precise and sustained medication delivery while minimizing damage to surrounding healthy cells.
Collaboration and Research Findings
This research was conducted by an international team that includes scientists from Monash University and Deakin University in Australia. The team combined nanoarchaeosome-based drug encapsulation with silicon nanotube-based intracellular delivery to create a targeted therapeutic system.
Experimental Results
Findings from experiments conducted on in vitro cell cultures and ex ovo chick embryo models were published in the journal Advanced Materials Interfaces. The studies demonstrated that the Nanoarchaeosome-Doxorubicin-Silicon nanotube platform induced significant cytotoxic effects against MCF-7 breast cancer cells while largely sparing healthy fibroblast cells.
Mechanism of Action
The platform was observed to cause cell-cycle arrest and necrosis in cancer cells. Additionally, it significantly reduced angiogenesis, the process by which tumors develop new blood vessels, by suppressing key pro-angiogenic factors associated with tumor growth. Notably, the platform exhibited an inhibitory concentration that was 23 times lower than that of free doxorubicin, indicating its higher potency at much lower doses.
Implications for Healthcare
Dr. Swathi Sudhakar, an assistant professor in the Department of Applied Mechanics and Biomedical Engineering at IIT Madras, emphasized the potential impact of this technology on healthcare delivery, particularly in low- and middle-income countries like India. By enabling targeted delivery of smaller drug doses with higher efficacy, this system could lower overall cancer treatment costs and improve the quality of life for patients.
Biocompatibility and Scalability
Unlike other nanoinjection systems made from carbon or titanium nanotubes, the silicon nanotube-based design is inherently biocompatible and non-toxic. This characteristic eliminates the need for additional surface modifications, making the technology more reliable and scalable for future clinical applications.
Next Steps in Research
The next phase of research will focus on in vivo testing, long-term toxicity studies, and regulatory assessments as the team works towards the preclinical and clinical translation of the platform. These steps are crucial for ensuring the safety and efficacy of the technology before it can be made widely available to patients.
Conclusion
The development of this precision nanoinjection platform by IIT Madras marks a significant advancement in breast cancer treatment. By providing a targeted and effective delivery method for anticancer drugs, this technology has the potential to revolutionize the way breast cancer is treated, particularly in regions with limited healthcare resources.
Note: The information presented in this article is based on research findings and may evolve as further studies are conducted.
